Peetz Christopher 4

What Happened

• Christopher Peetz, CEO of Mirum Pharmaceuticals (MIRM), converted restricted stock units (RSUs) into common shares on Jan 23, 2026 and had shares withheld to cover taxes; he then sold 6,831 shares in an open-market transaction on Jan 26, 2026 for $96.19 each, totaling $657,088.

Key Details

• Transaction dates: Jan 23, 2026 (RSU conversion and tax withholding) and Jan 26, 2026 (open-market sale).
• Open-market sale: 6,831 shares at $96.19 per share = $657,088 proceeds.
• RSU activity: 12,500 RSUs converted to shares (acquired); 12,500 shares were withheld/disposed at $0 to satisfy tax withholding obligations (footnote F2).
• Vesting note: RSUs vest 1/3 each year on the anniversary of Jan 23, 2024, fully vesting after three years (footnote F3). Each RSU equals one share (footnote F1).
• Shares owned after these transactions: not disclosed in the provided filing.
• Filing: Report filed Jan 27, 2026 for transactions on Jan 23 and Jan 26 — appears to have been filed promptly.

Context

• The Jan 23 transactions reflect conversion/vesting of RSUs and shares withheld for taxes (routine compensation-related actions), while the Jan 26 sale was an open-market disposition generating cash proceeds. For derivative entries like these, the filing shows conversion of awards and tax-withholding rather than a separate cash exercise.